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Abstract 
Background: Most prostate cancer patients develop castration-resistant prostate cancer (CRPC) 
after androgen deprivation therapy treatment. CRPC growth is mediated by androgen receptor 
signalling driven by primary androgens synthesized largely by the CYP17A1 enzyme. 
Objective: To evaluate the safety profile and dose limiting toxicities of ODM-204. 
Design, setting, and participants: In this open, uncontrolled, non-randomised, multicentre, 
tolerability and pharmacokinetic first-in-man phase I dose escalation study, patients with 
metastatic CRPC were randomised to receive ODM-204 in sequential cohorts of 5 dose levels 
(i.e. 50, 100, 200, 300, and 500 mg twice daily) concomitantly with prednisone. 
Intervention: ODM-204, a novel, orally administered investigational non-steroidal dual 
inhibitor of CYP17A1 and AR. 
Outcome measurements and statistical analysis: ODM-204 plasma concentrations, serum 
testosterone, and prostate-specific antigen (PSA) levels were evaluated and imaging of lesions 
was performed.  
Results and limitations: 60.9% of the twenty-three patients enrolled into the study experienced 
mild adverse effects (AEs) considered to be related to the study treatment, which were fatigue, 
increased/decreased appetite, nausea, asthenia, diarrhoea, and weight decrease. ODM-204 area 
under the curve (AUC0-12) values increased dose-dependently until the 300 mg dose. The AUC 
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was lower on day 8 after repeated dosing compared to day 1 from the 200 mg dose upwards. 
Decreases in testosterone levels were seen with ODM-204 treatment confirming androgen 
deprivation. 13% of patients also demonstrated a greater than 50% decrease in PSA at week 12 
and continued ODM-204 treatment for over a year. 
Conclusions: ODM-204 was well tolerated up to the highest evaluated dose. There were 
decreases in both testosterone and PSA levels suggesting preliminary antitumor activity in the 
treatment of CRPC. The pharmacokinetic properties of the molecule, however, prevent further 
development. 
Patient summary: This study looked at the safety of ODM-204, a novel dual inhibitor of 
CYP17A1 and the AR, in CRPC patients. ODM-204 treatment was found to be well tolerated 
and also reduced both serum testosterone and PSA levels, but the properties of the molecule 
prevent further development. 
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Introduction 
The androgen receptor (AR) signalling pathway plays a major role in prostate cancer (PCa), and 
androgen deprivation therapy (ADT) by surgical or chemical castration is the standard treatment 
for patients with advanced PCa. After initial treatment response most of the patients, however, 
develop castration-resistant prostate cancer (CRPC) with a poor prognosis [1, 2]. In recent years, 
several clinical trials have shown that the castration-resistant growth is driven, to a large extent, 
by continued AR signalling, and that CRPC remains sensitive to androgens because of the 
sensitization and amplification of AR signalling [3-8]. Thus, hormonal manipulation with AR 
blockers, in addition to steroid biosynthesis inhibitors reducing the activation of the AR-
mediated pathway [9], remain the core of CRPC treatment. 
Although castration leads to very low levels of circulating testosterone, androgens are still 
present in prostate cancer tissues at clinically relevant concentrations that activate AR signalling 
and promote tumour growth [10]. The synthesis of the primary androgens testosterone and 
dihydrotestosterone (DHT) requires a cascade of oxidative enzymes, with one of the key 
enzymes being CYP17A1. Consequently, CYP17A1 inhibitors have been designed for the 
treatment of androgen-dependent PCa. The only CYP17A1-inhibitor currently approved for the 
treatment of CRPC, abiraterone, has been shown to exhibit a significant overall survival benefit 
in a post-chemotherapy phase III study, but some abiraterone-resistant tumours still continue to 
present persistent AR activation [11, 12]. Therefore, there is a clear rationale for developing 
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treatments that target CYP17A1 and AR together, as this may provide a more effective response 
than targeting either one alone. 
Here, we present ODM-204, a novel, orally administered investigational non-steroidal dual 
inhibitor of CYP17A1 and AR that was shown to inhibit tumour growth in the murine VCaP 
CRPC xenograft model [13]. In this phase I dose escalation study, the safety profile of ODM-204 
was shown to be satisfactory, but its pharmacokinetic profile would bring significant challenges 
on the development path. 
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Patients and Methods 
Inclusion criteria 
Eligible patients were males over the age of 18 with metastatic progressive CRPC with ongoing 
androgen deprivation (ADT) therapy by gonadotropin-releasing hormone (GnRH) agonist or 
antagonist, or bilateral orchiectomy, and serum testosterone level < 50 ng/dl at screening, as well 
as metastatic disease documented by bone scan, computed tomography or magnetic resonance 
imaging, and an Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Disease 
progression was defined as rising PSA (progression defined by a minimum of two rising PSA 
levels with an interval of at least one week apart with the screening value ≥ 2 ng/ml), soft tissue 
disease progression as defined by RECIST 1.1 criteria, or 2 or more new bone lesions. Brain 
lesions were exclusionary. The patients had provided written informed consent and the study 
protocol was approved by independent ethics committees at each participating centre. The study 
was registered on ClinicalTrials.gov (NCT02344017). 
Study design and treatment 
This was an open, uncontrolled, non-randomised, multicentre, tolerability and pharmacokinetic 
first-in-man phase I dose escalation study of ODM-204 in patients with progressive metastatic 
CRPC. Escalating dose levels of ODM-204 (50, 100, 200, 300 and 500 mg twice daily) were 
administered in sequential cohorts of 3-6 subjects together with Prednison®. ODM-204 was 
taken orally twice a day with food (in the morning and evening) and 5 mg of Prednison® was 
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taken once or twice a day depending on the daily dose prior to study entry. The subjects who did 
not experience any dose-limiting toxicity (DLT) within 24 hours after the first dose continued 
ODM-204 treatment with b.i.d. dosing. DLTs were defined as any of the following toxicities 
graded according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) determined to be related to ODM-204 and occurring during the first 28 days of 
the study treatment: grade ≥ 3 toxicity, excluding haematological toxicities, nausea, vomiting 
and diarrhoea; grade ≥ 3 nausea, vomiting and diarrhoea uncontrolled with antiemetic and/or 
anti-diarrheal therapy; grade ≥ 3 haematological toxicity lasting for ≥ 7 days; grade ≥ 4 
thrombocytopenia and neutropenia; other laboratory values of  ≥ grade 3 which were judged 
clinically significant by the investigator, or any other toxicity which in the judgement of the 
investigator was viewed as a DLT. Once the safety of an administered dose was established, the 
next dose level was administered, and the patients with previous dose level were allowed to 
continue treatment with ODM-204 until progression or intolerable AEs. The next dose level was 
started after a minimum of 3 patients had completed 28 days of treatment and after safety review 
by the safety monitoring board (SMB). 
Pharmacokinetic assessments 
On day 1, blood samples were taken predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 h 
postdose after single dosing. On day 8 after repeated dosing, blood samples were taken predose 
and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 h. The plasma concentrations of ODM-204 were 
determined from the blood samples using liquid chromatography with tandem mass 
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spectrometry. AUC from time zero to 12 h, 24 h and infinity, maximum concentration (Cmax), 
time to reach maximum concentration (tmax) and elimination half-life (t½) were calculated using 
Phoenix WinNonlin software (Certara, Princeton, NJ, USA). 
Antitumor activity 
Serum total PSA concentration was determined every 4 weeks until 24 weeks and every 12 
weeks thereafter. In case of PSA progression, a confirmatory test was obtained 3-4 weeks later. 
PSA response and progression were evaluated using PCWG2 criteria for PSA progression. 
Testosterone concentrations were measured from blood samples on days 1, 8 and 29 after start of 
treatment, as well as on week 12, week 24 and every 12 weeks thereafter. 
Chest, abdomen and pelvic CT or MRI (as per investigator’s discretion) was performed at 
screening, week 12 and every 12 weeks thereafter to evaluate soft tissue disease progression as 
defined by RECIST 1.1 criteria. 
Statistical considerations 
Adverse events (AEs) reported after administration of the study treatment were classified by 
System organ classes (SOC) and preferred terms using the MedDRA dictionary. The number and 
proportion (%) of subjects experiencing each AE was tabulated. The AEs were graded by 
severity and causality. PK parameters were analysed after logarithm transformation and 95% 
confidence interval for the geometric mean will be calculated. Descriptive statistics for 
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continuous variables were: number of observations (N), mean (MEAN), standard deviation (SD), 
minimum (MIN), median, maximum (MAX). In PK variables also geometric mean (GMEAN) 
and coefficient of variation (CV) was calculated. Because log-normal distribution, the formula 
CV=100*square root(exp(variance of log-transformed data)-1) was used. 
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Results 
Patient characteristics and study drug exposure 
In total, 23 patients with CRPC were enrolled into the study between 17 February, 2015 and 22 
June, 2016, at four centres; three into the 50 mg twice daily dose level group, three into the 100 
mg twice daily dose level group, six into the 200 mg twice daily dose level group, seven into the 
300 mg twice daily dose level group, and four into the 500 mg twice daily dose level group. The 
cut-off date for the data included in this report was 21 December, 2017. Baseline demographics 
and disease characteristics are shown in Table 1. Median time on treatment was 12.1 weeks (0.3-
71.7 weeks). Nine (39%) patients continued treatment for more than 12 weeks, and 4 (17%) 
patients were still receiving treatment at the time of data cut-off. Adverse events 
Adverse events (AEs) were reported in all of the patients, and in 14 of the 23 patients (61%) 
these AEs were considered to be related to the study treatment. 22 (95%) of the patients suffered 
mild grade 1 AEs, 13 (57%) suffered moderate grade 2 AEs, and 7 (30%) suffered severe or life 
threatening grade 3-4 AEs. Of the serious AEs 3 (13%) were considered related to study 
treatment. The most common treatment related AEs were fatigue (22%), increased appetite 
(17%), nausea (17%), asthenia (9%), diarrhoea (9%), decreased appetite (9%), and weight 
decrease (9%). In 10 of the patients (43%) disease progression related AEs led to discontinuation 
from the study, while 6 (26%) patients were discontinued due to disease progression, 2 (9%) due 
to DLTs (drug hypersensitivity in one patient in the 300 mg cohort, and vomiting and nausea in 
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one patient in the 200 mg cohort), and 4 (17%) due to reasons classified as ‘other’. One patient in 
the 300 mg cohort died during the study period due to disease progression. In general, the 
occurrence of AEs was not deemed to be dose-dependent, as treatment related AEs, serious AEs, 
and discontinuations due to AEs were present in all the study groups in similar proportions. The 
most commonly reported AEs are shown in Table 2. Pharmacokinetics 
Pharmacokinetic parameters for ODM-204 were determined on day 1 and day 8. On day 1 the 
AUC0-12 of ODM-204 increased in a dose-dependent manner up to the 300 mg dose. At the 500 
mg dose level, a slight decrease in AUC0-12 was observed (Figure 1A). On day 8, AUC0-12 
increased up to the 300 mg twice daily dose with a slight decrease between the 100 mg and 
200 mg twice daily doses and a remarkable decrease at the 500 mg twice daily dose level. 
Notably, the AUC0-12 values were also greater on day 1 compared to day 8 from the 200 mg dose 
twice daily upwards. The Cmax values on both day 1 and day 8 reflected in general the respective 
AUC0-12 values (Figure 1B).Testosterone changes 
Testosterone decreases of over 50% compared to baseline were observed in all of the studied 
doses after 8 days of ODM-204 treatment, with a decrease of over 75% present in some patients 
in the 50, 300 and 500 mg twice daily dose groups (Figure 2). However, the testosterone 
decrease was not dose-dependent and all cohorts (except the 50 mg cohort) included patients 
who did not present testosterone decrease. The majority of the maximum testosterone decreases, 
including all of the decreases over 50%, were seen at day 8, after which the testosterone levels 
started to increase back to the baseline in most patients. PSA changes 
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PSA decreases were seen in 7 (30%) patients at week 4, and the median decrease was 47% (2-
99%). At week 12, 3 (13%) patients had PSA response with a 50% or higher reduction from 
baseline (Figure 3). Out of the seven patients that showed a PSA decrease at week 4, six 
continued ODM-204 treatment for at least 24 weeks without discontinuation due to an AE or 
disease progression, and three continued in the study for more than a year (Figure 4). 
Interestingly, one patient continued ODM-204 treatment for over 36 weeks without any initial 
PSA decrease, and three of the patients (patient ID: 2, 4, and 6; Figure 4) that had demonstrated 
initial PSA decrease were not discontinued from the study until several weeks after the point at 
which the PSA decrease had ended. The median time of ODM-204 treatment across cohorts was 
12.14 weeks. 
Imaging results of prostate lesions at week 12 showed that ODM-204 treatment resulted in a 
stable disease in one patient in the 50 and 200 mg twice daily group, and in two patients in the 
500 mg twice daily group. Additionally, ODM-204 treatment also resulted in a stable disease 
regarding bone lesions in one patient in all of the studied dose cohorts, except in the 200 mg 
twice daily cohort where four patients were reported to have a stable disease bone response. 
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Discussion 
In this first-in-man dose escalation trial ODM-204 was demonstrated to be generally well 
tolerated in CRPC patients, with doses up to 500 mg twice daily. One DLT occurred at the 300 
mg twice daily cohort but a maximum tolerated dose was not reached. The dose escalation was 
discontinued at the 500 mg twice daily dose level because of decreased ODM-204 plasma 
concentrations at the higher dose levels after repeated dosing on day 8 compared to single dosing 
on day 1. The most common treatment-related AEs, fatigue, increased/decreased appetite, 
nausea, asthenia, diarrhoea, and weight decrease, were generally of grade 1 and 2 in severity and 
without significant clinical consequence. The AE profile did not differ between dose levels. 
These AEs are in line with previous observations showing that AR inhibitors such as 
enzalutamide are associated with fatigue and gastrointestinal events [14, 15]. Interestingly, 
ODM-204 treatment did not demonstrate cardiac adverse events, which have been associated 
with the CYP17A1 inhibitor abiraterone [14]. Additionally, the incidence and severity did not 
appear to be directly dose-related nor related to differences in the ODM-204 plasma 
concentration. 
The interpretation of antitumor activity can be difficult in the setting of a phase I trial given that 
cohorts are small and doses variable, but the current study did provide some indication of the 
efficacy of ODM-204. Firstly, ODM-204 treatment resulted in a decrease of serum testosterone 
levels in most of the patients in all of the studied dose cohorts. As serum testosterone level 
monitoring is commonly used to verify response to ADT [16], this confirms the androgen 
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deprivation effect of ODM-204. Secondly, serum PSA levels were also decreased by ODM-204 
treatment in 30% of the patients with 13% showing a decrease of over 50% compared to the 
baseline. Thirdly, the imaging results showed that ODM-204 treatment resulted in a stable 
disease in four patients at week 12 as well as the arrest of bone lesion progressing in at least one 
patient in each dose cohort. Importantly, the patients demonstrating over 50% decrease in PSA 
continued ODM-204 treatment for over a year without discontinuation due to an AE or disease 
progression, which is an encouraging outcome. Taken together, these data suggest that dual 
inhibition of CYP17A1 and AR could be a valuable mechanism for treatment of prostate cancer 
patients [17]. 
Interestingly, the AUC (from the 200 mg dose upwards) and Cmax values of ODM-204 were 
unexpectedly greater on day 1 compared to day 8, contrary to what has been observed in the 
nonclinical studies in monkeys. At the 500 mg dose level, decreases in AUC values were also 
observed on both day 1 and day 8 suggesting a decrease in the steady state plasma concentration 
of ODM-204. This effect may be related to an induction of an elimination route caused by 
ODM-204, and it seems to become pronounced especially at the higher doses after an eight-day 
exposure to ODM-204. If so, the patients having less decrease in steady-state plasma 
concentrations should have better outcomes, and interestingly the patient (dosed 300mg twice a 
day) that had both the highest plasma concentrations and the lowest decrease in AUC by day 8 
used the CYP3A4 inhibitor ezetimibe [18]. Hence, the pharmacokinetic properties make the 
further development of the molecule challenging.  
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In conclusion, ODM-204 demonstrated an acceptable safety profile up to the highest tested dose 
500 mg twice daily as well as preliminary antitumor activity in some patients. Based on this 
study, no new trials are currently being planned with ODM-204. 
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Figure Legends 
Table 1. Patient characteristics at baseline. 
Table 2. Most common adverse events by dose (subject count and percentage). 
 
Figure 1. Pharmacokinetics of ODM-204. A) AUC0-12 and B) Cmax versus dose, mean+SD.  
Figure 2. Maximum testosterone changes during the first 4 weeks compared to baseline.  
Figure 3. Maximum PSA change (%) from baseline during 12 weeks. PSA = prostate-
specific antigen. 
Figure 4. Duration of ODM-204 treatment. Time in weeks spent in the study without 
discontinuation due to an AE or disease progression. Blue bars denote patients that demonstrated 
PSA decrease, and red bars denote patients that did not. 
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Tables and figures 
Table 1. Patient characteristics at baseline. 
Characteristics Total daily dose
a
     Total 
 
100 mg 
(N = 3) 
200 mg 
(N = 3) 
400 mg 
(N = 6) 
600 mg 
(N = 7) 
1000 mg 
(N = 4) 
(N = 23) 
Median age (range), years 74 (66–76) 70 (59–77) 68.5 (61–75) 69 (57–84) 71 (66–74) 70 (57–84) 
ECOG, n (%)       
0 1 (33) 1 (33) 4 (67) 3 (43) 3 (75) 12 (52) 
1 2 (67) 2 (67) 2 (33) 4 (57) 1 (25) 11 (48) 
BMI       
Median  25.1 30.8 31.5 29.7 27.4 29.8 
(kg/m
2
, min–max) (24–32) (26–31) (25–40) (21–32) (25–37) (21–40) 
PSA       
Median  149.6 50.0 26.7 94.4 19.1 46.5 
(ng/ml, min–max) (68.3–162.3) (14.5–210.9) (5.5–249.6) (7.2–194.7) (0.7–36.5) (0.7–249.6) 
Gleason score        
Low [2-4] 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 1 (4) 
Medium [5-7] 1 (33) 0 (0) 3 (50) 3 (43) 1 (25) 8 (35) 
High [8-10] 2 (67) 2 (67) 3 (50) 3 (43) 3 (75) 13 (57) 
Previous therapies, n (%)       
Chemotherapy 1 (33) 2 (67) 2 (33) 5 (71)  3 (75) 10 (43) 
Abiraterone 0 (0) 1 (33) 2 (33) 2 (29) 3 (75) 8 (35) 
Enzalutamide 0 (0) 1 (33) 2 (33) 5 (71) 3 (75) 4 (17) 
a
Administered twice daily. 
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Table 2. Most common adverse events by dose (subject count and percentage). 
Adverse event, n (%) Daily total dose
a
     Total 
 
100 mg 
(N = 3) 
200 mg 
(N = 3) 
400 mg 
(N = 6) 
600 mg 
(N = 7) 
1000 mg 
(N = 4) 
(N = 23) 
Decreased appetite  2 (67)  3 (43) 1 (25) 6 (26) 
Fatigue 1 (33) 1 (33) 2 (33) 1 (14) 1 (25) 6 (26) 
Nausea  1 (33) 2 (33) 2 (29) 1 (25) 6 (26) 
Diarrhoea  1 (33) 2 (33) 2 (29)  5 (22) 
Vomiting  1 (33) 1 (17) 2 (29) 1 (25) 5 (22) 
Asthenia  1 (33)  3 (43)  4 (17) 
Constipation  1 (33) 1 (17) 1 (14) 1 (25) 4 (17) 
Insomnia   1 (17) 2 (29) 1 (25) 4 (17) 
Weight decrease   1 (17) 1 (14) 2 (50) 4 (17) 
Abdominal pain    2 (29) 1 (25) 3 (13) 
Back pain   1 (17)  2 (50) 3 (13) 
Blood potassium decrease   1 (17) 1 (14) 1 (25) 3 (13) 
Depressed mood  1 (33)  1 (14) 1 (25) 3 (13) 
Pain in extremity 1 (33) 1 (33) 1 (17)   3 (13) 
a
Administered twice daily. 
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Figure 1. Pharmacokinetics of ODM-204. A) AUC0-12 and B) Cmax versus dose, mean+SD.  
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Figure 2. Maximum testosterone changes during the first 4 weeks compared to baseline.  
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Figure 3. Maximum PSA change (%) from baseline during 12 weeks. PSA = prostate-
specific antigen. 
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Figure 4. Duration of ODM-204 treatment. Time in weeks spent in the study without 
discontinuation due to an AE or disease progression. Blue bars denote patients that demonstrated 
PSA decrease, and red bars denote patients that did not. 
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Take home message 
In a phase I dose-escalation study, a dual inhibitor of CYP17A1 and the AR, ODM-204, was 
well tolerated and demonstrated antitumor activity by decreasing serum testosterone and PSA 
levels in patients with CRPC. The pharmacokinetic properties, however, prevent further 
development. 
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Table 1. Patient characteristics at baseline. 
Characteristics Total daily dose
a
     Total 
 
100 mg 
(N = 3) 
200 mg 
(N = 3) 
400 mg 
(N = 6) 
600 mg 
(N = 7) 
1000 mg 
(N = 4) 
(N = 23) 
Median age (range), years 74 (66–76) 70 (59–77) 68.5 (61–75) 69 (57–84) 71 (66–74) 70 (57–84) 
ECOG, n (%)       
0 1 (33) 1 (33) 4 (67) 3 (43) 3 (75) 12 (52) 
1 2 (67) 2 (67) 2 (33) 4 (57) 1 (25) 11 (48) 
BMI       
Median  25.1 30.8 31.5 29.7 27.4 29.8 
(kg/m
2
, min–max) (24–32) (26–31) (25–40) (21–32) (25–37) (21–40) 
PSA       
Median  149.6 50.0 26.7 94.4 19.1 46.5 
(ng/ml, min–max) (68.3–162.3) (14.5–210.9) (5.5–249.6) (7.2–194.7) (0.7–36.5) (0.7–249.6) 
Gleason score        
Low [2-4] 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 1 (4) 
Medium [5-7] 1 (33) 0 (0) 3 (50) 3 (43) 1 (25) 8 (35) 
High [8-10] 2 (67) 2 (67) 3 (50) 3 (43) 3 (75) 13 (57) 
Previous therapies, n (%)       
Chemotherapy 1 (33) 2 (67) 2 (33) 5 (71)  3 (75) 10 (43) 
Abiraterone 0 (0) 1 (33) 2 (33) 2 (29) 3 (75) 8 (35) 
Enzalutamide 0 (0) 1 (33) 2 (33) 5 (71) 3 (75) 4 (17) 
a
Administered twice daily. 
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Table 2. Most common adverse events by dose (subject count and percentage). 
Adverse event, n (%) Daily total dose
a
     Total 
 
100 mg 
(N = 3) 
200 mg 
(N = 3) 
400 mg 
(N = 6) 
600 mg 
(N = 7) 
1000 mg 
(N = 4) 
(N = 23) 
Decreased appetite  2 (67)  3 (43) 1 (25) 6 (26) 
Fatigue 1 (33) 1 (33) 2 (33) 1 (14) 1 (25) 6 (26) 
Nausea  1 (33) 2 (33) 2 (29) 1 (25) 6 (26) 
Diarrhoea  1 (33) 2 (33) 2 (29)  5 (22) 
Vomiting  1 (33) 1 (17) 2 (29) 1 (25) 5 (22) 
Asthenia  1 (33)  3 (43)  4 (17) 
Constipation  1 (33) 1 (17) 1 (14) 1 (25) 4 (17) 
Insomnia   1 (17) 2 (29) 1 (25) 4 (17) 
Weight decrease   1 (17) 1 (14) 2 (50) 4 (17) 
Abdominal pain    2 (29) 1 (25) 3 (13) 
Back pain   1 (17)  2 (50) 3 (13) 
Blood potassium decrease   1 (17) 1 (14) 1 (25) 3 (13) 
Depressed mood  1 (33)  1 (14) 1 (25) 3 (13) 
Pain in extremity 1 (33) 1 (33) 1 (17)   3 (13) 
a
Administered twice daily. 
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